All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
Introducing
Now you can personalise
your Lymphoma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
China Food and Drug Administration accept clinical trial application for JHL1101 in phase I and III trials in Non-Hodgkin Lymphoma
Bookmark this article
This month, on 4th April 2017, the China Food and Drug Administration (CFDA) accepted a Clinical Trial Application (CTA) by JHL Biotech for JH1101 in phase I and III clinical trials in NHL patients.1
JHL1101 is the first product in the company’s pipeline, and is a proposed biosimilar of rituximab.
JHL Biotech filed their application under the new guidelines for biosimilars issued in 2015 and data to support the CTA was produced at the company’s facility in Wuhan, China; the world's largest biopharmaceutical manufacturing facility based on single-use technologies.
In China, it is estimated that 80,000 cases of NHL are diagnosed each year.2
- Pharmaceutical Daily News. Sanofi’s partner JHL Biotech accepted for clinical trial in China. 2017 Apr 05. http://www.pharmaceuticaldaily.com/sanofis-partner-jhl-biotech-accepted-for-clinical-trial-in-china/. [Accessed 2017 Apr 11].
- Chen W. et al. Cancer statistics in China, 2015. CA: A Cancer Journal for Clinicians. 2016 Mar-Apr;66(2):115-32. DOI: 10.3322/caac.21338. Epub 2016 Jan 25.
More about...
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Thank youRelated articles
Newsletter
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox